China 
Africa 
Explore chapters and articles related to this topic
Sustainable Green Polymeric Nanoconstructs for Active and Passive Cancer Therapeutics
Published in Vladimir Torchilin, Handbook of Materials for Nanomedicine, 2020
Ankit Rochani, Sreejith Raveendran, D. Sakthi Kumar
As stated previously, most amphiphilic CDxs have modifiable functional groups and could be easily self-assembled to create NPs. This makes them suitable for developing FA/aptamer/monoclonal antibody tagged biomaterials, which can be used for developing cancer-targeted nanodrug delivery vectors. In a recent study, FA was conjugated with CDxs to obtain FA-CDx biomaterial. This was used for the development of paclitaxel-loaded FA-CDx NPs for targeted delivery of paclitaxel as a model drug against breast cancer (T-47D and ZR-75-1) cell lines with variable FA receptor expressions [117]. This system was also found to be effective against in mice model of metastatic breast cancer. This makes FA-CDxs an interesting nanodrug delivery vector for developing a generic formulation for other next-generation anticancer molecules [121]. However, the safety of these materials when delivered by parenteral route is an unexplored domain. Furthermore, per-6-thio-β-CDx (SH-CDx) was used as a noncovalent carrier of anticancer drug (β-Lapachone) and AuNPs. This drug and SH-CDx-complexed AuNPs were coated with anti-EGFR antibody-tagged PEG. This novel nanoconstruct was used for cancer-targeted drug delivery application and to achieve anticancer therapy by chemotherapy and photothermal ablation effects [122]. These studies clearly show CDx can be derivatized to develop cancer-targeted nanomedicines.
The Role of Nanoparticles in Cancer Therapy through Apoptosis Induction
Published in Hala Gali-Muhtasib, Racha Chouaib, Nanoparticle Drug Delivery Systems for Cancer Treatment, 2020
Marveh Rahmati, Saeid Amanpour, Hadiseh Mohammadpour
As mentioned before, various conditions such as physiological, pathological, and different environmental stimuli could induce ER stress and subsequently UPR to restore the homeostasis in cells. Recently, ER stress mediators have been more studied to find a new therapeutic target in cancers and autoimmune diseases [85, 86]. Several NPs could trigger the ER stress and the upregulation of UPR mediators. Metal NPs, such as silver NPs (AgNPs) and gold NPs (AuNPs), are promising candidates drug delivery systems in different disorders and could induce apoptosis through upregulation of ER stress mediators [87, 88]. In addition, numerous NPs have a potential to be used in disease treatment. For example, AgNPs that induce cell death apoptosis through ER stress pathway in MCF-7 and T-47D breast cancer cell line highlight a new potential strategy for the treatment of breast cancers [87]. ZnO NPs are also reported, because they cause ER stress by increasing the level of the misfolded protein, subsequently leading to apoptosis through constant activation of the UPR pathway [89].
Recent Advancements on Nano-Based Drug Delivery System for Targeted Cancer Therapy
Published in Pradipta Ranjan Rauta, Yugal Kishore Mohanta, Debasis Nayak, Nanotechnology in Biology and Medicine, 2019
These are class of compounds where a metal ion is sandwiched between two cyclopentadienyl complexes with an oxidation state of +2 giving the complex aromatic stability (Figure 10.4). Ferrocene is a metallocene of iron Fe(h5-C5H5)2 that does not show any cytotoxicity; the ferrocenium cation [Fe(h5-C5H5)2]þ, however, shows a substantial amount of cytotoxicity towards a broad range of cancerous cell lines (Kopf-Maier, Kopf, and Neuse 1984). This may be due to the mechanism of generating ROS inside the cancer cells, which in turn causes DNA damage and hinders the cell membrane integrity. Other researchers have designed a derivative of ferrocenyl iminosugar complex with a fucosidase inhibitor and found this to be significantly effective against melanoma cancer SK-MEL28 and triple-negative breast cancer MDA-MB-231 cell lines (Hottin et al. 2016). Likewise, another complex of ferrocene functionalized with hetero-metallic Pt(II)eguanidine was also found effective for inhibiting cancer cell growth. Very interestingly, it was effective against the cisplatin-resistant colorectal cancer WiDr cell line and breast cancer T-47D cells (Nieto et al. 2015).
Principal component-based image segmentation: a new approach to outline in vitro cell colonies
Published in Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization, 2023
Delmon Arous, Stefan Schrunner, Ingunn Hanson, Nina Frederike Jeppesen Edin, Eirik Malinen
Proprietary data (data set 1) were obtained from a flatbed laser scanner (Epson Perfection V850 Pro), providing images with a resolution of 2125 2985, 1200 dots per inch (dpi), 21.17µm/pixel spatial resolution and 48-bit depth. No prior filtering nor adjustments were performed on the captured images during scanning with the scanner software (EPSON Scan v3.9.3.3). Data set 1, including respective MCC and GT data, is publicly available in Zenodo’s repository (Arous et al. 2021). An example of cell colony image is provided in Figure 5. The cell flask contains cell colonies, as well as background structures (e.g. shadows) and outer contours of the T25 cell flask. The segmentation suggested by the ACC is delineated in red. The full data set consists of 16 cell culture flasks used for a colony formation assay of the T-47D (breast) cancer cell line.
Ultrasound-assisted green synthesis of triazole-based azomethine/thiazolidin-4-one hybrid inhibitors for cancer therapy through targeting dysregulation signatures of some Rab proteins
Published in Green Chemistry Letters and Reviews, 2023
Aboubakr H. Abdelmonsef, Ahmed M. El-Saghier, Asmaa M. Kadry
A survey of Tables S3–S10 (Supplementary file section) for Schiff base scaffolds 3a–d and 4a–d illustrated that the highest cytotoxic activities on most of the panel cell lines were achieved by compounds 3d and 4d as shown in Tables S6 and S10 (Supplementary file section). The results of compound 3d revealed high growth inhibition against leukemia cell line CCRF-CEM; breast cancer cell line T-47D at 62.55%, 50.41%. On the other hand, the results of compounds 4d at 47.85%, 40.85%. Moreover, compounds 3d and 4d revealed moderate growth inhibition of 39.22% and 33.49% against leukemia cell lines SR; 42.66% and 33.19% against non-small cell lung cancer cell lines HOP62; 25.74% and 34.61% against ovarian cancer cell line SK-OV-3, respectively.
Synthesis and cytotoxic activity of some novel benzocoumarin derivatives under solvent free conditions
Published in Green Chemistry Letters and Reviews, 2019
Anhar Abdel-Aziem, Huda Refaat Mahmoud Rashdan, Entesar Mohamed Ahmed, Sara N. Shabaan
The cytotoxic activity of eight compounds was determined by USA National Cancer Institute against different human cancer cell lines, using Adriamycin and 5-Florouracil as positive controls. The results are cited in Table 1 and revealed that pyrazole 4e exhibited powerful growth inhibition activity against Leukemia K-562 (48.45%), Melanoma MDA-MB-435 (47.79%) as well as Renal Cancer UO-31(40.70%). On the other hand, compounds 5a and 5c showed promising anticancer potency against Renal Cancer UO-31, Leukemia CCRF-CEM and Breast Cancer cell lines. However, compound 5d showed remarkable growth inhibitory activity against all of Leukemia cell lines specially K-562 (65.42%) and SR (75.26%). In addition to a pronounced anticancer activity towards Non-Small Cell Lung Cancer NCI-H522 (76.17%), Melanoma MDA-MB-435 (67.65%) and Breast Cancer MCF7 (64.38%). Moreover, compound 5e exhibited promising growth inhibition activities against several cancer cell lines including Leukemia K-562 (62.22%), SR (64.48%), Non-Small Cell Lung Cancer NCI-H522 (62.84%) as well as Melanoma SK6MEL-2 (60.45%). Furthermore, it showed potent anticancer activity against Renal Cancer UO-31 and Breast Cancer MCF by 47.03% and 53.04%, respectively. Moreover, pyrazole 9 showed moderate activity against Breast Cancer MCF7, Renal Cancer UO-31, Leukemia SR, Non-Small Cell Lung Cancer NCI-H460 and T-47D by 37.46%, 37.82%, 34.25%, 34.96% and 30.15%, respectively.